Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
| Class:Id | LiteratureReference:9702371 |
|---|---|
| _displayName | Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study |
| _timestamp | 2020-09-30 14:57:48 |
| author | [Person:9702338] Bigal, Marcelo E [Person:9702355] Dodick, David W [Person:9702380] Rapoport, Alan M [Person:9702377] Silberstein, Stephen D [Person:9702381] Ma, Yuju [Person:9702373] Yang, Ronghua [Person:9702363] Loupe, Pippa S [Person:9702351] Burstein, Rami [Person:9702347] Newman, Lawrence C [Person:9702348] Lipton, Richard B |
| created | [InstanceEdit:9702388] Jassal, Bijay, 2020-09-30 |
| journal | Lancet Neurol |
| pages | 1081-90 |
| pubMedIdentifier | 26432182 |
| title | Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study |
| volume | 14 |
| year | 2015 |
| (literatureReference) | [Reaction:9702354] CALCA(83-119) binds CALCA antibodies [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study (9702371)
